Differential pharmacology and benefit/risk of azilsartan compared to other sartans
about
Azilsartan as a Potent Antihypertensive Drug with Possible Pleiotropic Cardiometabolic Effects: A Review StudyAzilsartan Improves Salt Sensitivity by Modulating the Proximal Tubular Na+-H+ Exchanger-3 in MiceAzilsartan compared to ACE inhibitors in anti-hypertensive therapy: one-year outcomes of the observational EARLY registry.Changeover Trial of Azilsartan and Olmesartan Comparing Effects on the Renin-Angiotensin-Aldosterone System in Patients with Essential Hypertension after Cardiac Surgery (CHAOS Study).Safety, tolerability, and efficacy of azilsartan medoxomil with or without chlorthalidone during and after 8 months of treatment for hypertensionAdvances in understanding the renin-angiotensin-aldosterone system (RAAS) in blood pressure control and recent pivotal trials of RAAS blockade in heart failure and diabetic nephropathy.Critical evaluation of the efficacy and tolerability of azilsartan.Azilsartan medoxomil: a review of its use in hypertension.Pharmacokinetic evaluation and clinical utility of azilsartan medoxomil for the treatment of hypertension.An evaluation of the latest evidence relating to renin-angiotensin system inhibitors.Azilsartan medoxomil in the treatment of hypertension: the definitive angiotensin receptor blocker?New developments in the pharmacological treatment of hypertension: dead-end or a glimmer at the horizon?Pharmacokinetic-pharmacodynamic modeling of the antihypertensive interaction between azilsartan medoxomil and chlorthalidone in spontaneously hypertensive rats.Azilsartan Medoxomil, an Angiotensin II Receptor Antagonist for the Treatment of Hypertension.Spectrophotometric and spectrofluorimetric studies on azilsartan medoxomil and chlorthalidone to be utilized in their determination in pharmaceuticals.Azilsartan, an angiotensin II type 1 receptor blocker, restores endothelial function by reducing vascular inflammation and by increasing the phosphorylation ratio Ser(1177)/Thr(497) of endothelial nitric oxide synthase in diabetic mice.Novel mechanism for disrupted circadian blood pressure rhythm in a rat model of metabolic syndrome--the critical role of angiotensin II.A Practical Approach to Hypertension Management in DiabetesEvaluation of the angiotensin II receptor blocker azilsartan medoxomil in African-American patients with hypertension.Stability-indicating RP-LC method for determination of azilsartan medoxomil and chlorthalidone in pharmaceutical dosage forms: application to degradation kinetics.Improvement of Diurnal Blood Pressure Variation by Azilsartan.Divergent Spatiotemporal Interaction of Angiotensin Receptor Blocking Drugs with Angiotensin Type 1 Receptor.Azilsartan in Patients With Mild to Moderate Hypertension Using Clinic and Ambulatory Blood Pressure Measurements.
P2860
Q26740629-8EF93C29-6574-4880-9800-991A5A11FD37Q28602057-18B175A0-D622-4333-BCA9-1D5610FB8844Q35949950-8D4D482A-1A18-4CF4-A770-24463003D837Q37010254-23FDBDAE-236A-404A-A32D-9D4D3B10AE5DQ37257463-16A0C740-7048-48C1-9698-CF995BDCC223Q37720499-16287CE3-B52C-4AFA-AE9E-79B74FD1208CQ38015816-7EFAF854-D162-4B06-984B-1A429FA41604Q38033252-0D6DF1C9-9CEE-4245-A85A-46BF69E7231CQ38079623-D9A67D9E-2C44-4936-AACD-FEDC24667924Q38096442-ED55EC03-1C29-479C-821C-62DC0B08CB48Q38144197-019CFFF8-0B3A-4538-A323-3A21801F4D45Q38429870-2684D5EF-E630-4082-B341-D9FD43473814Q38965224-565AAF87-7591-4D97-9FDE-08A2A4C8EED9Q39264079-CFC56FAF-5596-4DFF-AF35-394111FC42F0Q39657942-B8C4C82E-96F5-46AF-A415-4DF3869E3DD1Q41922933-3AF991EC-AF81-4B21-B7F6-91392F609144Q42235582-0E6D2233-7D4A-4C22-BBAF-997DCA11B24DQ42371757-69B37D64-D9CD-4D76-93AE-8F67A5150748Q45058875-34C4E7F3-5B2F-40E2-98B4-D40C50AD0190Q45323794-24A088D3-CAF2-4DEE-B2CE-21D94FBBFE25Q47142567-5C234D4B-8807-42FA-92B0-185D7A4E237DQ47383912-DDB8F4FE-FCD5-4EBC-8E49-6EF04AF2984DQ54119402-C4982487-6907-4B6B-B978-0B9A2F56EF07
P2860
Differential pharmacology and benefit/risk of azilsartan compared to other sartans
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Differential pharmacology and benefit/risk of azilsartan compared to other sartans
@ast
Differential pharmacology and benefit/risk of azilsartan compared to other sartans
@en
type
label
Differential pharmacology and benefit/risk of azilsartan compared to other sartans
@ast
Differential pharmacology and benefit/risk of azilsartan compared to other sartans
@en
prefLabel
Differential pharmacology and benefit/risk of azilsartan compared to other sartans
@ast
Differential pharmacology and benefit/risk of azilsartan compared to other sartans
@en
P2860
P921
P356
P1476
Differential pharmacology and benefit/risk of azilsartan compared to other sartans
@en
P2093
Takashi Kajiya
Theodore W Kurtz
P2860
P304
P356
10.2147/VHRM.S22595
P407
P577
2012-02-28T00:00:00Z